QGEN - Qiagen N.V. Forward Price-to-Revenue Multiple

QGEN (Qiagen) - company brandmark

Qiagen N.V. dominates the DNA diagnostics segment due to its extensive installed base of equipment. The forward P/S ratio reflects the market valuation of these assets, where the value 3.40 describes the current level. Revenue is based on a "razor-and-blade" model through the sale of consumables, while production automation ensures stable operating leverage and predictable business growth.

QGEN qiagen.com: Projected Price to Revenue in the range 07/04/2022 - 11/16/2026

QGEN (qiagen.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Fundamental company valuation:Qiagen N.V. QGEN
Product sample of Qiagen N.V.

The non-cyclical nature of Qiagen N.V. (QGEN) business in molecular diagnostics ensures a stable revenue stream, minimizing the impact of macroeconomic shocks. The forward P/S ratio compares market capitalization with projected sales volume, allowing for an assessment of the cost of each unit of future revenue. By analyzing the company's expected P/S chart, an investor determines the degree of overpayment for the asset, finding the equilibrium point between risk and growth potential.

Competitor analysis for Qiagen N.V.

Forward P/S Multiple TEM (Tempus Labs)|Forward Price to Sales IONS|RGEN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Avidity Biosciences RNA|CRSP: Forward P/S Multiple|Market Cap to Projected Revenue WGS|RARE (Ultragenyx Pharma) - Forward P/S Multiple|Forward P/S Multiple Beam Therapeutics Inc.|Price-to-Projected Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Projected Revenue|10x Genomics Inc - Forward Price-to-Revenue Multiple|NTLA (Intellia Therapeutics, Inc.) - Future Price to Revenue|Stoke Corp - Forward P/S Multiple|BLFS (BioLife) - Market Cap to Projected Revenue|wavelifesciences.com (WVE) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prime Medicine Corp (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.